PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Imara to lay off all but six employees

Massachusetts-based biotech Imara will be laying off 83% of its workforce after its top drug candidate fell short in clinical trials.

The recent regulatory filing with the SEC states that all but six Imara employees will be laid off by the end of the second quarter. It also says that the workforce change is meant to reduce the company’s operating expenses while it strategizes how to move forward following the disappointment of recently shared phase 2 trial results.

The drug, tovinontrine, was meant to treat blood diseases such as beta-thalassemia, sickle cell disease, and heart failure. Earlier this month, the company decided to stop its development for all three indications after the drug failed to provide meaningful benefit in trials.

While a few biotechs have made similar announcements recently, it seems that Imara has been marching toward this day for a long time, with drug disappointments dating back a few years. At the same time, a public market downturn has made it so that companies are trading below market value, putting pressure on companies to reduce expenses.

Imara’s shares are currently trading at $1 a piece, compared to $47 in mid-2021.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026